T-DXd Rechallenge After Grade 1 ILD Appears Safe, Study Finds
OptiTROP-Breast05: Sacituzumab Tirumotecan Shows 71% ORR in Advanced TNBC
Neoadjuvant Pepinemab Primes Tumor Immunity